Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
 |
New Vision (Kampala) - October 11, 2002
Geoffrey Kamali
Merck Sharp & Dohme (MSD), German producers of Crixivan, one of the HIV drugs, has introduced new packaging for its low priced products to Africa.
The anti-retrovirals are sold by major producers to a number of developing countries under the Accelerated Access Initiative, managed by the UNAIDS programme.
It is expected that other major producers of antiretrovirals will take similar action, making it difficult for middlemen to sell back the drugs to high priced markets in Europe.
021011
NV021009
Copyright © 2002 - The New Vision. All articles are republished on AEGIS by permission. Material may not be redistributed, posted to any other location, published or used for broadcast without written authorization from Managing Director/Editor-in-chief, The New Vision, P.O. Box 9815, Kampala - Uganda, Tel/fax: 256-41-235221, E-mail: wpike@newvision.co.ug.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .